12-Lipoxygenase
12-lipoxygenase (12-LOX) is an enzyme that oxidizes fatty acids, generates proinflammatory metabolites and has been implicated in a myriad of diseases including Heparin-Induced Thrombocytopenia (HIT) and Type 1 Diabetes (T1D). We are developing therapies for these diseases with a clinical program in HIT, preclinical program in T1D and discovery research aimed at expanding our 12-LOX inhibitors to additional diseases.
Learn More about the TargetHeparin-Induced Thrombocytopenia (HIT)
HIT is a deadly syndrome characterized by hyperactivated platelets and a devastating pro-thrombotic state. Targeting 12-LOX inhibits the production of 12-HETE, a proinflammatory metabolite known to play a role in platelet activation and thrombosis. We received Orphan Designation and Fast Track Designation for our first-in-class drug product, VLX-1005, addressing the underlying cause of this immune-driven blood clotting.
Learn MoreType 1 Diabetes (T1D)
We are developing a disease-modifying therapy for T1D. By inhibiting 12-LOX and shutting down production of its products like 12-HETE, Ī² cells are able to function properly by producing more insulin and becoming more resilient to immune attack.
Learn MoreMeet the Team
Recent News
Veralox Therapeutics Announces EMA Orphan Drug Designation for VLX-1005
— Receives New Designation for Treatment of Platelet-Activating Anti-Platelet Factor 4 (PF4) DisordersĀ — Complements FDA Orphan Drug Designation and Fast Track Designation for VLX-1005 Frederick, MD, Aug. 14, 2024 … Read More
Veralox Names Jonathan Mow as Chief Executive Officer as the Company Advances Development of First-in-Class Therapies for Immune-Mediated Diseases in Conjunction with Financing
— New Financing of $24 Million Fully Funds the Phase 2 Clinical Program for Lead Candidate VLX- 1005 — Company Prepares to Evaluate VLX-1005 in Heparin-Induced Thrombocytopenia (HIT) FREDERICK, Md., … Read More
Veralox Therapeutics Announces Favorable Results of Phase 1 Studies of VLX-1005 in Development for Treatment of Heparin-Induced Thrombocytopenia
Development program for VLX-1005, a novel small molecule 12-LOX inhibitor, awarded Fast Track designation by US Food and Drug Administration FREDERICK, Md., June 13, 2022 — Veralox Therapeutics, a biotechnology … Read More